View ValuationAdicon Holdings 향후 성장Future 기준 점검 4/6Adicon Holdings (는) 각각 연간 30.6% 및 9.6% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 29.7% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 15.8% 로 예상됩니다.핵심 정보30.6%이익 성장률29.73%EPS 성장률Healthcare 이익 성장17.3%매출 성장률9.6%향후 자기자본이익률15.75%애널리스트 커버리지Good마지막 업데이트02 Apr 2025최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updates공고 • May 30ADICON Holdings Limited Announces Yeh Richard as the Lead Independent Non-Executive Director, Effective May 27, 2026ADICON Holdings Limited announced that Mr. YEH Richard, an independent non-executive Director, had been designated as the lead independent non-executive Director with effect from May 27, 2026. Mr. YEH is currently the chairman of the audit committee and a member of the nomination committee of the Board. The responsibilities of the lead independent non-executive Director are not different from or greater than those of other independent non-executive Directors. Mr. YEH’s primary responsibility as the lead independent non-executive Director is to facilitate and strengthen communication among the independent non-executive Directors, between the independent non-executive Directors and the other members of the Board, and with the shareholders (in particular, the minority shareholders). The position of the lead independent non-executive Director is not an executive position in the Company, and the holder of such position does not have any management role in the Group. The designation of the lead independent non-executive Director is introduced with reference to the amended Corporate Governance Code as set out in Appendix C1 to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, which became effective on July 1, 2025. As at the date of this announcement, the Board comprised Mr. WANG Legang as an executive Director; Ms. YANG Ling, Mr. LIN Jixun, Mr. LI Bo and Mr. ZHOU Mintao as non-executive Directors; and Mr. MI Brian Zihou, Mr. YEH Richard and Mr. ZHANG Wei as independent non-executive Directors.공고 • Mar 26Adicon Holdings Limited (SEHK:9860) acquired 10% stake in Astrabio.Adicon Holdings Limited (SEHK:9860) acquired 10% stake in Astrabio on August 23, 2025. Adicon Holdings Limited (SEHK:9860) completed the acquisition of 10% stake in Astrabio on August 23, 2025.공고 • Mar 25Adicon Holdings Limited, Annual General Meeting, May 31, 2026Adicon Holdings Limited, Annual General Meeting, May 31, 2026.공고 • Mar 13Adicon Holdings Limited to Report Fiscal Year 2025 Results on Mar 25, 2026Adicon Holdings Limited announced that they will report fiscal year 2025 results on Mar 25, 2026공고 • Feb 13Adicon Holdings Limited Announces Appointment of Wang Legang as Executive Director and Member of Strategy Committee, Effective February 13, 2026Adicon Holdings Limited announced that with effect from February 13, 2026, Mr. WANG Legang has been appointed as an executive Director of the Company. Mr. WANG has been appointed as the chief operating officer and the general manager of the Group since August 15, 2025 and he will continue to act as the chief operating officer and the general manager of the Group. Mr. WANG, aged 45, has extensive experience in healthcare business management and digital transformation. Early in his career, from July 2004 to March 2009, Mr. WANG was a pharmaceutical engineer at Qingdao Huanghai Pharmaceutical Co. Ltd. From March 2009 to July 2014, Mr. WANG served as a regional manager and marketing manager at Pfizer (China) Investment Co. Ltd. He then served as a regional director responsible for pharmaceutical sales of Merck (China) Investment Co. Ltd. from July 2014 to March 2018, before becoming a vice president of the Medlinker, a role he held from March 2018 to February 2021 mainly in charge of the group’s business management and digital pharmaceutical sales networks development. From February 2021 to September 2024, he served as the senior vice president of Cowell Health and also led the interactive medicine and innovative drug division of the group as a general manager. From April 2025 to August 2025, Mr. WANG served as the deputy general manager of the Jointown Pharmaceutical Group and the general manager of Jiuyi Clinic (Hubei) Co. Ltd. Mr. WANG obtained a bachelor’s degree in clinical pharmacy from Harbin Medical University in the People’s Republic of China in June 2004 and finished EMBA courses from Ocean University of China in November 2014. A service agreement has been entered into between Mr. WANG and the Company for a term of three years commencing from his appointment. Mr. WANG’s appointment as an executive Director shall be subject to retirement by rotation and re-election at the annual general meeting of the Company in accordance with the Company’s articles of association. With effect from February 13, 2026, Mr. WANG has been further appointed by the Board as a member of the strategy committee of the Board.공고 • Nov 13Adicon Holdings Limited (SEHK:9860) entered into a definitive agreement to acquire Crown Bioscience, Inc. from Crown Bioscience International.Adicon Holdings Limited (SEHK:9860) entered into a definitive agreement to acquire Crown Bioscience, Inc. from Crown Bioscience International on November 13, 2025. This strategic move will enable Crown Bioscience to operate as a standalone entity under Adicon's ownership. Crown Bioscience's Global Biospecimens business, headquartered in Hamburg, Germany, with facilities in Frederick, MD, will remain fully integrated within JSR Life Sciences. The transaction is subject to customary closing conditions and is expected completion of the transaction is in 2026.공고 • Aug 22Adicon Holdings Limited Appoints Zhu Jonathan as Non-Executive Director and Member of the Strategy Committee of the Board, with Effect from August 22, 2025The board of directors of ADICON Holdings Limited announced that: With effect from August 22, 2025, Mr. ZHU Jonathan ("Mr. ZHU") has been appointed as a non-executive Director and is responsible for providing professional opinion and judgment to the Board. The biographical details of Mr. ZHU are as follows: Mr. ZHU, aged 57, has extensive experience in the industrial and medical diagnostic industries. Early in his career, from 1992 to 1996, Mr. ZHU was with the US Air Force (USAF). From June 1996 to September 1998, he was the China general manager at Environmental Elements Corporation. He then served as a senior lobbyist at EOP Group Inc. in Washington, D.C. from June 2000 to June 2005, before becoming a corporate director at HORIBA Group, a role he held from June 2005 to January 2010. From September 2014 to October 2022, he led the APAC healthcare and life sciences practice as regional managing partner at Heidrick & Struggles. Since November 2022, Mr. ZHU has been the APAC managing partner of the life sciences practices at Korn Ferry (Sg) Pte Ltd. Mr. ZHU currently serves as a senior advisor to AdvaMed. His previous advisory appointments include senior advisor to The Carlyle Group (NASDAQ: CG) from 2019 to July 2025, and advisor to the chairman of Shenzhen Hepalink Pharmaceutical Co. Ltd. from 2020 to 2024, and member of the Asia advisory board of Coloplast from 2013 to 2021. Mr. ZHU obtained a bachelor's degree in engineering from University of Maryland in the United States in May 1992, an MBA from University of Baltimore in the United States in May 2000 and a master's degree in laws from China University of Political Science and Law in China in 2012. With effect from August 22, 2025, Mr. ZHU has been further appointed as a member of the strategy committee of the Board.공고 • Aug 12Adicon Holdings Limited to Report First Half, 2025 Results on Aug 22, 2025Adicon Holdings Limited announced that they will report first half, 2025 results on Aug 22, 2025공고 • Mar 31Adicon Holdings Limited, Annual General Meeting, May 31, 2025Adicon Holdings Limited, Annual General Meeting, May 31, 2025.공고 • Mar 20Adicon Holdings Limited to Report Fiscal Year 2024 Results on Mar 31, 2025Adicon Holdings Limited announced that they will report fiscal year 2024 results on Mar 31, 2025공고 • Aug 20Adicon Holdings Limited to Report First Half, 2024 Results on Aug 30, 2024Adicon Holdings Limited announced that they will report first half, 2024 results on Aug 30, 2024공고 • Jun 01Adicon Holdings Limited Approves Appointment of Mr. Zhou Mintao as A Non-Executive DirectorAdicon Holdings Limited at the Annual General Meeting approved appointment of Mr. ZHOU Mintao as a non-executive director of the Company. executive Director has been approved by the Shareholders at the 2024 AGM. Mr. ZHOU has entered into a letter of appointment with the Company for a term of 3 years commencing from May 30, 2024 subject to the articles of association of the Company and the Listing Rules. Pursuant to the appointment letter entered into by Mr. ZHOU with the Company, he is entitled to receive a remuneration of RMB732,000 annually with discretionary bonus for his directorship with the Company with reference to his duties and responsibilities towards the Company and prevailing market conditions. Upon Mr. ZHOU's appointment as a non-executive Director, the Board has resolved to appoint Mr. ZHOU as the chairman of the strategy committee of the Board with effect from May 30, 2024 and accept the resignation of Ms. YANG Ling as the chairwoman of the Strategy Committee on the same date. Ms. YANG will continue to serve as a member of the Strategy Committee.공고 • Mar 29Adicon Holdings Limited, Annual General Meeting, May 31, 2024Adicon Holdings Limited, Annual General Meeting, May 31, 2024.공고 • Mar 20Adicon Holdings Limited to Report Fiscal Year 2023 Results on Mar 28, 2024Adicon Holdings Limited announced that they will report fiscal year 2023 results on Mar 28, 2024이익 및 매출 성장 예측OTCPK:ADCN.F - 애널리스트 향후 추정치 및 과거 재무 데이터 (CNY Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/20273,900395N/AN/A312/31/20263,696281N/A486712/31/20253,158194N/A651412/31/20242,91447113230N/A9/30/20243,01713690220N/A6/30/20243,11922566210N/A3/31/20243,209230139294N/A12/31/20233,298235212378N/A9/30/20233,678324426641N/A6/30/20234,059412639904N/A3/31/20234,460546617898N/A12/31/20224,861681596893N/A12/31/20213,380316408564N/A12/31/20202,742284375482N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: ADCN.F 의 연간 예상 수익 증가율(30.6%)이 saving rate(2.8%)보다 높습니다.수익 vs 시장: ADCN.F 의 연간 수익(30.6%)이 US 시장(16.8%)보다 빠르게 성장할 것으로 예상됩니다.고성장 수익: ADCN.F 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.수익 대 시장: ADCN.F 의 수익(연간 9.6%)이 US 시장(연간 12.9%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: ADCN.F 의 수익(연간 9.6%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: ADCN.F의 자본 수익률은 3년 후 15.8%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YHealthcare 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2025/05/18 14:18종가2025/02/18 00:00수익2024/12/31연간 수익2024/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Adicon Holdings Limited는 7명의 분석가가 다루고 있습니다. 이 중 7명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Bo LiBofA Global ResearchShuo SongCitic Securities Co., Ltd.Binbin ZhangCitic Securities Co., Ltd.4명의 분석가 더 보기
공고 • May 30ADICON Holdings Limited Announces Yeh Richard as the Lead Independent Non-Executive Director, Effective May 27, 2026ADICON Holdings Limited announced that Mr. YEH Richard, an independent non-executive Director, had been designated as the lead independent non-executive Director with effect from May 27, 2026. Mr. YEH is currently the chairman of the audit committee and a member of the nomination committee of the Board. The responsibilities of the lead independent non-executive Director are not different from or greater than those of other independent non-executive Directors. Mr. YEH’s primary responsibility as the lead independent non-executive Director is to facilitate and strengthen communication among the independent non-executive Directors, between the independent non-executive Directors and the other members of the Board, and with the shareholders (in particular, the minority shareholders). The position of the lead independent non-executive Director is not an executive position in the Company, and the holder of such position does not have any management role in the Group. The designation of the lead independent non-executive Director is introduced with reference to the amended Corporate Governance Code as set out in Appendix C1 to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, which became effective on July 1, 2025. As at the date of this announcement, the Board comprised Mr. WANG Legang as an executive Director; Ms. YANG Ling, Mr. LIN Jixun, Mr. LI Bo and Mr. ZHOU Mintao as non-executive Directors; and Mr. MI Brian Zihou, Mr. YEH Richard and Mr. ZHANG Wei as independent non-executive Directors.
공고 • Mar 26Adicon Holdings Limited (SEHK:9860) acquired 10% stake in Astrabio.Adicon Holdings Limited (SEHK:9860) acquired 10% stake in Astrabio on August 23, 2025. Adicon Holdings Limited (SEHK:9860) completed the acquisition of 10% stake in Astrabio on August 23, 2025.
공고 • Mar 25Adicon Holdings Limited, Annual General Meeting, May 31, 2026Adicon Holdings Limited, Annual General Meeting, May 31, 2026.
공고 • Mar 13Adicon Holdings Limited to Report Fiscal Year 2025 Results on Mar 25, 2026Adicon Holdings Limited announced that they will report fiscal year 2025 results on Mar 25, 2026
공고 • Feb 13Adicon Holdings Limited Announces Appointment of Wang Legang as Executive Director and Member of Strategy Committee, Effective February 13, 2026Adicon Holdings Limited announced that with effect from February 13, 2026, Mr. WANG Legang has been appointed as an executive Director of the Company. Mr. WANG has been appointed as the chief operating officer and the general manager of the Group since August 15, 2025 and he will continue to act as the chief operating officer and the general manager of the Group. Mr. WANG, aged 45, has extensive experience in healthcare business management and digital transformation. Early in his career, from July 2004 to March 2009, Mr. WANG was a pharmaceutical engineer at Qingdao Huanghai Pharmaceutical Co. Ltd. From March 2009 to July 2014, Mr. WANG served as a regional manager and marketing manager at Pfizer (China) Investment Co. Ltd. He then served as a regional director responsible for pharmaceutical sales of Merck (China) Investment Co. Ltd. from July 2014 to March 2018, before becoming a vice president of the Medlinker, a role he held from March 2018 to February 2021 mainly in charge of the group’s business management and digital pharmaceutical sales networks development. From February 2021 to September 2024, he served as the senior vice president of Cowell Health and also led the interactive medicine and innovative drug division of the group as a general manager. From April 2025 to August 2025, Mr. WANG served as the deputy general manager of the Jointown Pharmaceutical Group and the general manager of Jiuyi Clinic (Hubei) Co. Ltd. Mr. WANG obtained a bachelor’s degree in clinical pharmacy from Harbin Medical University in the People’s Republic of China in June 2004 and finished EMBA courses from Ocean University of China in November 2014. A service agreement has been entered into between Mr. WANG and the Company for a term of three years commencing from his appointment. Mr. WANG’s appointment as an executive Director shall be subject to retirement by rotation and re-election at the annual general meeting of the Company in accordance with the Company’s articles of association. With effect from February 13, 2026, Mr. WANG has been further appointed by the Board as a member of the strategy committee of the Board.
공고 • Nov 13Adicon Holdings Limited (SEHK:9860) entered into a definitive agreement to acquire Crown Bioscience, Inc. from Crown Bioscience International.Adicon Holdings Limited (SEHK:9860) entered into a definitive agreement to acquire Crown Bioscience, Inc. from Crown Bioscience International on November 13, 2025. This strategic move will enable Crown Bioscience to operate as a standalone entity under Adicon's ownership. Crown Bioscience's Global Biospecimens business, headquartered in Hamburg, Germany, with facilities in Frederick, MD, will remain fully integrated within JSR Life Sciences. The transaction is subject to customary closing conditions and is expected completion of the transaction is in 2026.
공고 • Aug 22Adicon Holdings Limited Appoints Zhu Jonathan as Non-Executive Director and Member of the Strategy Committee of the Board, with Effect from August 22, 2025The board of directors of ADICON Holdings Limited announced that: With effect from August 22, 2025, Mr. ZHU Jonathan ("Mr. ZHU") has been appointed as a non-executive Director and is responsible for providing professional opinion and judgment to the Board. The biographical details of Mr. ZHU are as follows: Mr. ZHU, aged 57, has extensive experience in the industrial and medical diagnostic industries. Early in his career, from 1992 to 1996, Mr. ZHU was with the US Air Force (USAF). From June 1996 to September 1998, he was the China general manager at Environmental Elements Corporation. He then served as a senior lobbyist at EOP Group Inc. in Washington, D.C. from June 2000 to June 2005, before becoming a corporate director at HORIBA Group, a role he held from June 2005 to January 2010. From September 2014 to October 2022, he led the APAC healthcare and life sciences practice as regional managing partner at Heidrick & Struggles. Since November 2022, Mr. ZHU has been the APAC managing partner of the life sciences practices at Korn Ferry (Sg) Pte Ltd. Mr. ZHU currently serves as a senior advisor to AdvaMed. His previous advisory appointments include senior advisor to The Carlyle Group (NASDAQ: CG) from 2019 to July 2025, and advisor to the chairman of Shenzhen Hepalink Pharmaceutical Co. Ltd. from 2020 to 2024, and member of the Asia advisory board of Coloplast from 2013 to 2021. Mr. ZHU obtained a bachelor's degree in engineering from University of Maryland in the United States in May 1992, an MBA from University of Baltimore in the United States in May 2000 and a master's degree in laws from China University of Political Science and Law in China in 2012. With effect from August 22, 2025, Mr. ZHU has been further appointed as a member of the strategy committee of the Board.
공고 • Aug 12Adicon Holdings Limited to Report First Half, 2025 Results on Aug 22, 2025Adicon Holdings Limited announced that they will report first half, 2025 results on Aug 22, 2025
공고 • Mar 31Adicon Holdings Limited, Annual General Meeting, May 31, 2025Adicon Holdings Limited, Annual General Meeting, May 31, 2025.
공고 • Mar 20Adicon Holdings Limited to Report Fiscal Year 2024 Results on Mar 31, 2025Adicon Holdings Limited announced that they will report fiscal year 2024 results on Mar 31, 2025
공고 • Aug 20Adicon Holdings Limited to Report First Half, 2024 Results on Aug 30, 2024Adicon Holdings Limited announced that they will report first half, 2024 results on Aug 30, 2024
공고 • Jun 01Adicon Holdings Limited Approves Appointment of Mr. Zhou Mintao as A Non-Executive DirectorAdicon Holdings Limited at the Annual General Meeting approved appointment of Mr. ZHOU Mintao as a non-executive director of the Company. executive Director has been approved by the Shareholders at the 2024 AGM. Mr. ZHOU has entered into a letter of appointment with the Company for a term of 3 years commencing from May 30, 2024 subject to the articles of association of the Company and the Listing Rules. Pursuant to the appointment letter entered into by Mr. ZHOU with the Company, he is entitled to receive a remuneration of RMB732,000 annually with discretionary bonus for his directorship with the Company with reference to his duties and responsibilities towards the Company and prevailing market conditions. Upon Mr. ZHOU's appointment as a non-executive Director, the Board has resolved to appoint Mr. ZHOU as the chairman of the strategy committee of the Board with effect from May 30, 2024 and accept the resignation of Ms. YANG Ling as the chairwoman of the Strategy Committee on the same date. Ms. YANG will continue to serve as a member of the Strategy Committee.
공고 • Mar 29Adicon Holdings Limited, Annual General Meeting, May 31, 2024Adicon Holdings Limited, Annual General Meeting, May 31, 2024.
공고 • Mar 20Adicon Holdings Limited to Report Fiscal Year 2023 Results on Mar 28, 2024Adicon Holdings Limited announced that they will report fiscal year 2023 results on Mar 28, 2024